Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug PharmaphorumCelcuity has won FDA approval for gedatolisib - its first product - as a treatment for patients with a particular form of breast cancer.OncologyRead full story pharminent July 15, 2026 (Last updated: July 16, 2026) Pharmaphorum Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s Tau-Targeting Alzheimer’s Data Show Promise — and Raise QuestionsNext: AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
